Premium
The potential of N‐methylpyrrolidone to prevent osteoporosis and enhance bone regeneration in vivo (1139.5)
Author(s) -
Gjoksi Bebeka,
Ghayor Chafik,
Weber Franz
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1139.5
Subject(s) - ovariectomized rat , osteoporosis , endocrinology , medicine , bone mineral , bone resorption , osteoclast , in vivo , resorption , osteocalcin , apposition , dose , chemistry , hormone , alkaline phosphatase , biology , receptor , biochemistry , microbiology and biotechnology , enzyme
Osteoporosis is a chronic, skeletal disease highly prevalent in post‐menopausal women influenced by hormonal factors causing a huge burden on health care in an aging society. We previously demonstrated that NMP is a bioactive drug which enhances bone regeneration in vivo and acts as an enhancer of bone morphogenetic protein (BMP) in vitro. NMP also inhibits osteoclast differentiation and attenuates bone resorption. The present study used animal models established for the evaluation of enhanced osteoporosis through double ovariectomy (OVX) and treated systemically with different doses of (NMP). With this treatment we want to describe the preventive effect of NMP on bone mass loss. Female Sprague‐Dawley rats with an approximate weight of 220‐250g were randomly divided into sham‐operated group (Sham) either treated or not with NMP and four ovariectomized subgroups as OVX (control), OVX treated with three different graded doses of NMP. Bilateral ovariectomy or Sham operations were performed as previously designated and the weight of the animals was measured weekly. We assessed the pharmacological effects of NMP against osteoporosis by evaluating the body weight, serum biochemical parameters, bone mineral density (BMD), dynamic histomorphometry of bone and bone histomorphology. The results showed that over a 15 week period, in OVX rats the increase in body weight, serum osteocalcin levels and decreases of BMD were significantly reversed by NMP treatment. Additionally, the effect of the three different treatment dosages of NMP correlated dose‐dependently with their effect on bone resorption. Mineral apposition rate (MAR) showed the protective activity of NMP through promotion of bone formation and suppression of bone resorption. These results suggest that NMP has a remarkable antiosteoporotic activity, and may be a promising candidate for treatment of postmenopausal osteoporosis induced by estrogen deficiency. Grant Funding Source : Swiss National Science Foundation